Kornimate/medical-research-clean huggingface dataset:
interest of fluorescence in salvage surgery for recurrence of head and neck cancer in irradiated area

Conditions: Head and Neck Cancer

Summary: treatment of head and neck squamous cell carcinoma often combines chemoradiotherapy when organ has to be preserved or when surgery is not indicated. the loco-regional failure is about 30%. then salvage surgery is the only chance for patients to survive but the overall survival rate is only 29% at 24 months. this prognostic is bad because of poor local control which is non-optimized by a complementary radiotherapy and negative exeresis margins. currently, there is no intraoperative technique to better visualize the tumor limits in real time. with fluorescence techniques, an accurate mapping of tumor extension can be considered. recently, atallah et al. (2015) demonstrated the use of fluorescence during a head and neck surgery in mice, as a tool allowing for better surgical margins. digonnet et al (2015) found a tumor fragment after an injection of indocyanine green (icg) intravenously in salvage surgery for patient with head and neck cancer. the ability of icg to detect a surgical margin positive intraoperatively has never be evaluated in irradiated area. the aim of this pilot study is to evaluate the interest of fluorescence in salvage surgery for recurrence of head and neck cancer in irradiated area.


Eligibility criteria:
inclusion criteria: * patient over 18 years old * head and neck squamous cell carcinoma confirmed by biopsy * non metastatic disease * resectable tumour * locoregional recurrence or new localization in pre irradiated territory at a dose ≥ 50 gy with or without chemotherapy * haematological constants, liver function and kidney function adapted in the 15 days before inclusion: * haemoglobin ≥ 9 g / dl * polymorphonuclear neutrophils ≥ 1.5 x 10 9 * platelet ≥ 100 x 109 / l * total bilirubin ≤ 1.5 times upper limit of normal (uln) * alt and ast \<3 times uln * alkaline phosphatase ≤ 2.5 times uln * serum creatinine \ 55 ml / min (method of cockcroft) * absence of proteinuria * who 0 or 1 * signed informed consent form * patient affiliated to the social security system. exclusion criteria: * patient considered as non eligible for a salvage surgery * metastatic disease * hypersensitivity to indocyanine green or allergy to seafood or reaction to iodinated contrast agents * pregnant or breastfeeding women

Keywords: head and neck neoplasms recurrence indocyanine green salvage surgery
herbal tonic fertile supplement(zo2c5)

Conditions: Male Infertility

Summary: the purpose of this study is to determine whether the effect of mixed herbals drug (citrus, citrolus vol, lan, carrot seed, zingiber, onion, basil, cinnamon) administration on male infertility: oligospermia

in the last few years, a marked decrease in the quality of semen has been reported. infertility is one of the major health problems in 10 to 15% of couples' lives; from which approximately 50% of couple's infertility is due to male factors. the aim of the present study was to evaluate an herbal mixed effects on spermatogenesis and the normal production of sperm. researchers have reported that using antioxidants and vitamins a, b, c, e, flavonoids, sulfur compounds, terpenoids and phenolic compounds in the daily diet can protect sperm. in this study the investigators aimed to assess synergistic effect of these herbal compounds in male infertility. 700 mg tablet for 180 consequence days/daily will be advising, for 40 patients semen samples in 1th and 180 day after treatment will take, in andrology lab according who method:samples put into 2 ml of medium (hams f10) containing 0.5% bovine serum albumin. after 5 min incubation at 37oc (with 5% co), the sperm samples were determined using the standard haemocytometric method, and sperm motility was analyzed by microscope (olympus ix70) at 10 field and reported as the mean of motile sperm according to who methods . the sperm abnormality was evaluated according to the standard method of narayana .briefly, smears of the sperm suspension were made on clean glass slides and stained with periodic acid-schiff's reaction haematoxylin. the stained smears were observed under a light microscopic with 40× magnification. the sperms were classified into normal and abnormal. the total sperm abnormality was expressed as percentage incidence. other biochemical tests will be doing according the our research protocol and thesis for blood samples for measure lh, testosterone, tac, glc and cholesterol.

Eligibility criteria:
inclusion criteria: * all patients suffering from oligospermia are included exclusion criteria: * any diseases

Keywords: male infertility,oligo spermia
online diabetic foot support program- care kit

Conditions: Diabetes Mellitus; Diabetic Foot Ulcer; Diabetic Foot

Summary: the aim of this project is to examine the effects of the online diabetic foot support program (diafootsup) and care kit applied to type 2 diabetic individuals who have previously had a diabetic foot ulcer on diabetic foot outcomes (diabetic foot knowledge level, foot care behavior level, foot care self-efficacy level, hba1c, etc.).

it was planned as a randomized controlled study to determine the effect of the online diabetic foot support program (diafootsup) and care kit applied to type 2 diabetic individuals who had previously had diabetic foot ulcers on diabetic foot outcomes. the sample calculation of the study was based on determining the difference between two independent groups and the sample size for the experimental and control groups was taken as experimental: 31-control: 31 people using the g\*power 3.1.9.6 program. the experimental group was given a foot care kit developed by the researcher, which included special foot care products. pre-test data for the experimental and control groups are collected from the diabetic foot knowledge scale, foot care behavior scale, and diabetic foot care self-efficacy scale. online diabetic foot care training consisting of 5 modules is given individually to the patients in the experimental group. after the training, motivational messages and informative videos are sent once a week for 3 months. patients are also asked to send photos while doing foot care. the post-test data of the experimental and control groups will be collected at the end of 3 months with the diabetic foot knowledge scale, foot care behavior scale, and diabetic foot care self-efficacy scale. training videos will be delivered to the control group at the end of the study.

Eligibility criteria:
inclusion criteria: * 18 years of age or older, individuals diagnosed with type 2 diabetes, patients who have had diabetic foot ulcers and have healed, can read and write turkish, no visual, hearing, perception and any physical disability, physical, mental and cognitive competence to participate in self-care activities, able to use technological products (able to use computers, tablets and smartphones), individuals who voluntarily agree to participate in the study will constitute the sample exclusion criteria: * patients with active diabetic foot ulcers, individuals who cannot read or write, individuals who cannot use technological devices, individuals who do not want to participate in the study

Keywords: diabetic foot type 2 diabetes nursing education foot
is ifn-beta treatment in ms useful after a washout period in patients with neutralizing antibodies to interferon beta

Conditions: Relapsing-Remitting Multiple Sclerosis

Summary: this study is to find out if interferon-beta (ifn-beta) can recover its effectiveness after a washout period in patients with multiple sclerosis who have previously developed neutralizing antibodies to interferon-beta

this is an explorative multi-centre, open label, non-comparative trial investigating whether it is possible to recover ifn-beta efficacy in breakthrough relapsing-remitting multiple sclerosis patients with high titres of neutralizing ifn-beta antibodies. prior to enrollment, treated ms subjects must have been on interferon-beta-1a or interferon-beta-1b for a minimum of 12 months and have reduced bioavailability as defined by the relative expression of mxa mrna/gapdh. subjects will complete a washout period with concurrent methylprednisolone 500mg po daily for 3 days every month until they become neutralizing antibody negative. subjects will then be challenged with avonex 30mcg im weekly. bioavailability will be measured every three months to determine return of biological activity. clinical and mri parameters, safety and tolerability will be compared to baseline to determine efficacy.

Eligibility criteria:
inclusion criteria: * must have been receiving interferon-beta-1a or interferon-beta-1b for a minimum of 12 consecutive months prior to enrollment * relapsing-remitting multiple sclerosis according to poser or mcdonald criteria * edss score of 6 or less * nab titre \>or equal to 20 via cpe assay or \>or equal to 100 via mxa protein assay measured at least 24 hours after last interferon-beta injection on two consecutive tests at least 3 months apart * reduced bioavailability (relative expression of mxa mrna/gapdh exclusion criteria: * history of severe allergic or anaphylactic reaction to human albumin, to any interferon, methylprednisolone or to any other component of study drugs * clinically significant systemic illness * history of poorly controlled hypertension, diabetes, or osteoporosis * history of uncontrolled seizures within 3 months of enrollment * history of depression or suicidal ideation within 3 months of enrollment * serious local infection (abscess or cellulitis) or systemic infection within 8 weeks of study * abnormal screening blood tests

Keywords: recovery of efficacy mxa protein neutralizing antibodies multiple sclerosis
combined bleaching technique: efficacy and tooth sensitivity

Conditions: Tooth Bleaching; Tooth Sensitivity

Summary: the aim of this clinical study is to evaluate the efficacy and dental sensitivity associated with combined bleaching technique (in-office + at-home) varying in-office bleaching application under two different time protocols, and dentifrice containing arginine 8% and carbonate calcium use. one hundred eight participants who meet the study inclusion criteria will be selected. the desensitizing agent used will be a dentifrice containing 8% arginine and calcium carbonate. in each evaluation will be determined: tooth sensitivity and color. the data collected will be submitted to the factorial statistical analysis for evaluation of color and chi-square test for tooth sensitivity (α = 5%).

this study will be conducted under the consort recommendations. after approval by the ethics committee for research duly registered, the trial will be conducted in the clinic of dental school at the federal university of goias located in goiania. one hundred eight participants 108 volunteers will be selected on the criteria that qualify inclusion and exclusion from the study will be reported all volunteers were examined not qualify under the criteria for inclusion as part of the initial according to consort recommendations . after signing the signed an informed consent form all volunteer participants will receive a dental prophylaxis with pumice and water in a rubber cups for the removal of extrinsic stains two weeks before the beginning of tooth whitening.

Eligibility criteria:
inclusion criteria: * upper and lower anterior teeth without restorations; * upper and lower anterior teeth that have never undergone a bleaching procedure and are a2 or darker in color compared to the vita classical). exclusion criteria: * presence of primary and/or secondary carious lesion (s) on upper and lower anterior teeth; * presence of non-carious lesions, such as abfraction, erosion and abrasion; * presence of clinically visible cracks or defects of dental enamel on the dental surfaces of the upper and lower anterior teeth; * use of fixed orthodontic appliances; * presence of tooth sensitivity classified as equal to or greater than mild; * presence of severe dental dimming; * presence of parafunctional habits; * presence of any oral pathology; * smokers; * pregnant and lactating women
effect of hypotensive anesthesia on the perfusion index

Conditions: Controlled Hypotension for Nasal Surgeries

Summary: controlled hypotension has been used as a mean of reducing intraoperative blood loss and better visualization of the surgical field in nasal surgeries. perfusion index has been considered a useful tool for monitoring changes in peripheral perfusion using masimo set and serum lactate for central perfusion. many medications were used to induce hypotension. in this study we will compare the effects of tridil and labetalol on the perfusion.

the purpose of this study to detect the degree of hypotension that helps the surgeon and dosen't impair patient's perfusion and to compare the hypotensive effects of both tridil and labetalol infusions on the perfusion.

Eligibility criteria:
inclusion criteria: * asa i-ii males and females aged 18-45 years who were scheduled for functional endoscopic sinus surgery (fess) exclusion criteria: * uncontrolled hypertension, cerebrovascular disorders, bleeding and coagulation disorders, coronary artery diseases, renal or hepatic diseases or known hypersensitivity to the drugs used and pregnant.

Keywords: controlled hypotension, perfusion
cyberknife radiosurgery for locally recurrent prostate ca

Conditions: Recurrent Prostate Cancer

Summary: the purpose of this study is to scientifically evaluate the effects (good and bad) of a new type of radiation treatment in patients with locally recurrent prostate cancer after prior radiotherapy. the treatment is known as prostate radiosurgery, and is distinguished from traditional radiotherapy by the application of smaller, more precisely controlled margins around the area targeted for full dose radiation, and far fewer treatments, using a much larger dose per treatment. this research is being done to see what advantages, if any, prostate radiosurgery may have over other salvage treatment methods, including brachytherapy, cryosurgery, high intensity focused ultrasound (hifu), hormonal therapy and radical prostatectomy.


Eligibility criteria:
inclusion criteria: * histologically confirmed recurrent adenocarcinoma of the prostate, clinical stage t1 - t3 (ajcc 6th edition, see appendix ii), nx/n0, m0, following prior prostate radiotherapy. * karnofsky performance status \>80. * greater than 5 year life expectancy * greater than 2 years since the original course of radiotherapy. * absence of distant metastases by radiologic or pathologic assessment. * absence of lymph node involvement by radiologic or pathologic assessment. * patients must sign a study-specific informed consent form prior to study entry. exclusion criteria: * stage t4 disease (ajcc 6th edition, see appendix ii). * less than 2 years since the original course of radiotherapy. * lymph node involvement (n1). * evidence of distant metastases (m1). * radical surgery for carcinoma of the prostate * previous or concurrent cancers other than basal, in situ, or squamous cell skin cancers unless disease-free for ≥ 5 years. * major medical or psychiatric illness, which in the investigator's opinion, would prevent completion of treatment and would interfere with follow-up. * history of inflammatory bowel disease * late gi or gu morbidity \> grade 1 from the prior course of radiotherapy
pas in subacute sci

Conditions: Spinal Cord Injuries; Spinal Cord Diseases

Summary: the investigators have recently shown in incomplete sci patients that long-term paired associative stimulation is capable of restoring voluntary control over some paralyzed muscles and enhancing motor output in the weak muscles. in this study, the investigators will administer long-term paired associative stimulation to patients with incomplete cervical level sci at the subacute stage, and investigate its effectiveness for upper extremity rehabilitation.


Eligibility criteria:
inclusion criteria: 1. sci caused by an external trauma or sci caused by nontraumatic non-progressive disease of the spinal cord 2. cervical level injury, tetraplegia 3. time from injury/onset of symptoms 1-4 months 4. medical condition stable 5. residual neural connectivity in upper extremity: some voluntary activity in finger muscles or meps obtainable from distal hand muscles exclusion criteria: 1. diagnosed brain damage, visible in mri or ct. 2. no activity in hands/fingers and no meps recorded from distal hand muscles. 3. epilepsy 4. metal inclusion in the head area 5. high intracranial pressure 6. pacemaker 7. implanted hearing device 8. progressive diseases of spinal cord or brain (e.g. malignant tumors, degenerative diseases). 9. history of malignant tumor within the past 5 years. 10. previous head or spinal cord injury affecting the motor performance of upper extremities. 11. congenital anomaly in the anatomical structure of spinal canal/cord or dura. 12. significant systemic disease or other condition that could cause neurological deficit, or may affect subject's capability to undergo investigation-related procedures. 13. acute severe infection. 14. contraindications for mri. 15. current severe psychiatric diseases. 16. current chronic drug and/or alcohol abuse. 17. pregnancy. 18. severe emergency care polyneuropathy 19. pressure ulcer affecting the subject's capability to undergo the procedure safely
effects of specific pelvic stabilization exercise in postpartum pregnancy-related pelvic girdle pain women

Conditions: Pelvic Girdle Pain

Summary: postpartum women with ppgp receiving specific pelvic stabilization exercise training with transabdominal sonography-guided biofeedback would have better improvements on muscle functions, physical functions, pain, and disability compared to the regular pelvic stabilization exercise group


Eligibility criteria:
inclusion criteria: * postpartum : ≥ 3 months * pregnancy-related pelvic pain * pain location is located between posterior iliac crest and gluteal fold * clinical screening test for pelvic pain : aslr : positive and si joint ≥ 2 (+ symphysis ≥ 1) exclusion criteria: * lumbar or pelvic surgery * other causes of pelvic pain (such as fractures) * radiculopathy * other health problems, such as cancer, cardiovascular disease, rheumatism , etc * daily activities limited , unable to complete the experiment * communication disorders * mental disorder * pregnancy * have been trained in stable muscle strength in the past.
prostaglandin e1 (liprostin) treatment with lower limb angioplasty for peripheral arterial occlusive disease

Conditions: Peripheral Vascular Disease

Summary: this is the first clinical research trial in which intravenous prostaglandin e1 (pge1 is a vasoactive hormone) will be used as supportive treatment along with the angioplasty procedure to treat or open up a blocked artery within one lower limb or the most affected of two limbs in subjects with peripheral arterial occlusive disease.

paod results in a decrease in arterial blood flow to the lower limb and feet with symptoms that can include, pain at rest, a numbing sensation in limb or feet, limited ability to walk before pain occurs. paod can occur along with diabetic ulcers. proposed treatment will be given at a medical center with an overnight hospital stay. treatment includes angioplasty to open up one or two occluded arteries in a lower limb plus a drug (liprostin) a special formulation of liposomal prostaglandin e1,or pge1, a natural occuring vasoactive hormone). drug treatment is given twice to each artery to be treated, just before and after angioplasty. when angioplasty procedure is completed, a 12 hour intravenous infusion of liprostin is given to complete the treatment procedure. a total of 12 paod subjects will be enrolled in a single center: memorial hermann hospital, houston, tx. study will begin in february, 2003 with the last (12th) subject to be enrolled, likely by august, 20

Eligibility criteria:
inclusion criteria: * male or female subjects, 18 years and older * diagnosis of peripheral arterial occlusive disease \[paod\] * subject is a candidate for immediate angioplasty of the lower limb * subject must complete 2 treadmill tests at screen in which walking distance is limited by paod and not due to angina or fatigue exclusion criteria: * lower limb peripheral re-vascularization procedures in past 3 months * history of myocardial infarction in the past 6 months * malignant disease, uncontrolled hypertension or class iii heart failure * aortic occlusion, thrombosed popliteal aneurysm, severe hemorrhagic disorder, or a long iliac occlusion

Keywords: angioplasty & pge1 treatment of peripheral vascular disease
nudging, healthy diet and physical activity

Conditions: Obesity

Summary: the present study is a randomized school-based trial of a sample of 5th and 6th grade students from 10 public schools in the municipality of duque de caxias, metropolitan area of rio de janeiro, brazil. the aim is to investigate whether adding nudging actions to the intervention group of paappas trial (paapas study, nct02711488) increase fruits, vegetables and water consumption and daily energy expenditure, in a factorial design.


Eligibility criteria:
inclusion criteria: 5th and 6th grades students consent form signed by parents/tutors exclusion criteria: pregnant girls
stent coverage and neointimal tissue characterization after extra long everolimus - eluting stent implantation

Conditions: Ischemic Heart Disease; Coronary Artery Disease; Coronary Atherosclerosis

Summary: the objective of this study is to evaluate the rate of synergy 48 mm stent strut coverage and assess neointimal progression via oct measurement in patients who underwent pci.

patients with stable, unstable angina and non-st-elevation acs will be included in this study. patient will undergo coronary angiography for coronary anatomy assessment and estimation indications for pci . after screening an oct-guided pci with extra long synergy stent implantation will be provided in all patients. patient will be divided into 2 groups of follow-up and will be followed within 3 and 6 month after procedure. final clinical follow-up will be assessed at 12 month for all patients. at each follow-up visits the data regarding clinical events, coronary angiography and oct-imaging will be collected.

Eligibility criteria:
inclusion criteria: * signed written informed consent before study procedures * subject is eligible for percutaneous coronary intervention (pci) * left ventricular ejection fraction (lvef) \>30% * reference vessel diameter (rvd) ≥2.25 mm and ≤4.0 mm * target lesion(s) length must be ≥38 mm * target lesion(s) stenosis ≥50% exclusion criteria: * history of acute or recent stroke (\<2 months) * contraindications for antiplatelet and/or anticoagulant therapy * bleeding within the last 30 days * subject has acute st elevation mi (stemi) * subject has cardiogenic shock, hemodynamic instability requiring inotropic or mechanical circulatory support * subject with out of range complete blood count (cbc) values determined as a clinically significant * subject has documented or suspected liver disease, including laboratory evidence of hepatitis * subject has baseline serum creatinine level \>2.0 mg/dl (177µmol/l) * subject has signs or symptoms of active heart failure (i.e., nyha class iv) at the time of the index procedure * subject is a woman who is pregnant or nursing (a pregnancy test must be performed within 7 days prior to the index procedure in women of child-bearing potential) * lesion located within a saphenous vein graft or an arterial graft * subject has unprotected left main coronary artery disease (\>50% diameter stenosis) * other serious medical illness (e.g., cancer, congestive heart failure) that may reduce life expectancy to less than 12 months

Keywords: optical coherence tomography healing score neointimal coverage synergy 48 long lesion